LOGO

You are here: 

 



 

  • Photocure proposes dividend and share buyback program

    The Board of Directors of Photocure ASA decided on the 27th of October 2009 to initiate a share buyback program under the existing power of attorney. The Board also decided to propose call an extraordinary dividend of NOK 4.00 per share.

    >> Read more28.10.09

  • The Norwegian Pharmaceutical Pipeline is growing

    For the third year running the Norwegian Bioindustry Association has conducted a survey of The Norwegian Pharmaceutical Pipeline. There has been a growth of companies involved in clinical trials phase I and II, while the same number of companies is managing clinical trials in phase III.

    >> Read more04.10.09

  • Photocure divests Metvix to Galderma for EUR 51 million

    Photocure ASA has entered into agreements with Galderma S.A., under which Galderma has purchased global rights, assets, and liabilities related to Metvix and Metvixia, as well as the exclusive right to develop new dermatology products based on Photocure's patented substance, MAL.

    >> Read more01.10.09

  • Norwegian life science needs government's financial commitment

    Access to capital is the most pressing challenge facing emerging life sciences companies in the Norway. The sector now needs a financial commitment from Government in order to reinvigorate the investment environment for SMEs, according to the Annual Survey from the Norwegian Bioindustry Association.

    >> Read more28.09.09

  • New CFO in Navamedic ASA

    Torbjörn Sannerstedt has been appointed as the new CFO of Navamedic. Before Navamedic, Torbjörn Sannerstedt held the CFO position at AcadeMedia Company.

    >> Read more23.09.09

  • EMEA recommends application from Clavis Pharma

    The European Medicines Agency (EMEA) has recommended orphan drug designation to Intravenous CP-4126 for the treatment of pancreatic cancer. Clavis Pharma is currently conducting a Phase II study with Intravenous CP-4126 in patients with pancreatic cancer.

    >> Read more14.09.09

  • Algeta signs $800 million agreement with Bayer

    Algeta ASA has entered into a global agreement with Bayer for the development and commercialization of Algeta's first in class alpha-pharmaceutical, Alpharadin. Alpharadin is currently being evaluated in a global phase III trial in men with hormone-refractory prostate cancer (HRPC) that has spread to the bone.

    >> Read more03.09.09

  • Hexvix has been granted priority review by the FDA

    Photocure announces that the US Food and Drug Administration (FDA) has designated priority review for the Hexvix New Drug Application (NDA). FDA assigns priority review to products they consider to provide a significant improvement over current standard of care.

    >> Read more03.09.09

  • 50 millioner til forskning i næringslivet

    Brukerstyrt innovasjonsarena (BIA) lyser ut 50 millioner kroner til nye prosjekter i 2010. Søknadsfristen er 25. november. 

    >> Read more02.09.09

  • First patient included in trial of Amphitex

    PCI Biotech Holding ASA announces that the first cancer patient has received treatment in the Phase I/II trial with Amphinex®, used in PCI Biotech's unique technology for targeted enhancement of therapeutics in cancer treatment.

    >> Read more30.08.09

Showing from 41 to 50 of total 80 articles

Norwegian Bioindustry Association

Middelthuns gt. 27, Postboks 7072 Majorstuen, NO-0306 Oslo Tel: +47 23 08 88 00 / +47 23 08 88 18 / +47 91 10 54 91 Email: biotek@norskindustri.no Fax: +47 23 08 88 98